Summary
Background Topical photodynamic therapy (PDT) is widely used to treat superficial nonmelanoma skin cancer and dysplasia, and is generally well tolerated. However, as with all treatments, adverse effects may occur and awareness may facilitate approaches to prevention and management. Objectives To review the available evidence relating to the adverse effects of topical PDT, to help inform recommendations in updated clinical guidelines produced by the British Association of Dermatologists and British Photodermatology Group, and the efficacy of preventative and therapeutic approaches. Methods This review summarizes the published evidence related to the adverse effects of topical PDT and attempts to interpret this evidence in the context of patient risk and management. Results Pain and discomfort during PDT are acute adverse effects, which can be minimized through the use of modified and low-irradiance PDT regimens and do not therefore usually limit successful treatment delivery. Other adverse effects include the risk of contact allergy to photosensitizer prodrugs, although this is rare but should be kept in mind, particularly for patients who have received multiple PDT treatments to larger areas. There are no other significant documented longer-term risks and, to date, no evidence of cumulative toxicity or photocarcinogenic risk. Conclusions Topical PDT is usually well tolerated, reinforcing the utility of this important therapeutic option in dermatology practice. The main acute adverse effect of pain can typically be minimized through preventative approaches of modified PDT regimens. Other adverse effects are uncommon and generally do not limit treatment delivery.
What's already known about this topic?
• Photodynamic therapy (PDT) is widely used in dermatology.
• Pain is the most well documented adverse effect.
• Methods of effective pain relief are limited.
What does this study add?
• This review scrutinizes the literature relating to adverse effects of PDT and management approaches.
• PDT-induced pain can usually be effectively prevented and managed through adjustments to PDT regimens, such as using lower irradiance light delivery.
• Phototoxic reactions are to be expected.
• Other adverse effects are typically uncommon and not limiting.
Topical photodynamic therapy (PDT) is widely used to treat superficial nonmelanoma skin cancer and dysplasia. As with any therapeutic approach, the benefit/risk profile must be taken into account on an individual patient basis; in general, PDT is well tolerated. Historically, PDT-induced pain has been a potentially limiting factor, but with optimization of treatment parameters, such as the introduction of lower irradiance regimens, pain is now uncommonly a major issue. Expected 'adverse' effects of a phototoxic insult also include inflammation, manifest as erythema, exudation and sometimes urticaria. Other side-effects are uncommon and include scarring, altered hair growth or pigmentary change and allergic reactions. The theoretical risk of carcinogenesis with cumulative PDT treatments is unproven; indeed, PDT can be considered as a prophylactic approach in high-risk patients, such as the immunosuppressed. This review summarizes the current evidence relating to the adverse effects of topical PDT as part of the guideline updating project on this subject 1 , and interprets this evidence in the context of patient risk (Table 1) .
Pain Characteristics and frequency
PDT exerts its effects through a phototoxic mechanism; as part of this, pain and inflammation occur. With some of the more conventional higher irradiance topical PDT regimens, pain during irradiation is almost invariable. The mechanisms of PDTinduced pain are poorly understood, but studies in an adenocarcinoma cell line in vitro demonstrated preferential uptake of 5-aminolaevulinic acid (ALA) by beta-amino acid and c-aminobutyric acid transporters, which was not seen with methyl aminolaevulinate (MAL); this may be one possible explanation for the neurogenic nature of the pain experienced during ALA-PDT, although this was in a cell line model and has not been substantiated in humans. 2 In contrast, MAL uptake has been shown, in a human colon adenocarcinoma cell line, to be mediated by active transport mechanisms involving nonpolar amino acids, providing a potential rationale for any differences in pain mechanisms and experience during PDT following photosensitization by either ALA or MAL. 3 While there have only been limited studies of the mechanisms of PDT in human skin, it is clear that there is oxidative stress and generation of reactive oxygen species, and an inflammatory reaction involving the release of histamine, nitric oxide, prostaglandin E 2 , tumour necrosis factor-a and other cytokines; these may also be implicated in the pain and discomfort during and after PDT. 2, [4] [5] [6] In addition, a neurogenic mechanism involving transient receptor potential (TRP) channels has been implicated. [7] [8] [9] A recent study also showed mechanistic differences between ALA and MAL, in that ALA-PDT appeared to induce pain via singlet oxygen-mediated lipid peroxidation, in turn triggering nociceptor activation via TRP cation channel subfamily V member 1 (TRPV1) receptors in dorsal root ganglia in vitro. Furthermore, the TRPV1 inhibitor menthol reduced action potentials evoked by ALA-PDT in dorsal root ganglia and pain behaviour in a mouse model, although this was not the case with MAL-PDT. 10 In humans, PDT-induced pain begins almost immediately after irradiation starts. Commonly, patients describe a prickling, stinging, sharp burning sensation, most similar to that reported by patients with erythropoietic protoporphyria. 11, 12 There is large interindividual variation in the degree and nature of PDT-induced pain experienced by patients, although approximately 16-20% will report severe pain with conventional PDT. [13] [14] [15] [16] The multifactorial nature of PDT-induced pain and relative limitations of effective treatment options are well described. 17 In one study that looked retrospectively at experience related to almost 1000 PDT treatments, 44% of patients required some form of pain-reducing intervention. 18 Indeed, in two separate studies -one a survey of PDT services in Scotland and the other a prospective cohort study -of patients treated with PDT for superficial basal cell carcinoma (BCC), squamous cell carcinoma (SCC) in situ or actinic keratosis (AK), 28-38% of patients reported moderate-to-severe pain (score > 6 on a 0-10 numerical rating scale). 19, 20 Most of these data are derived from conventional topical PDT regimens using hospital-based, relatively higher irradiance light delivery. However, the PDT procedure is generally very well tolerated, with the pain in the majority of cases resolving once the irradiation period ends [7-9 min with the most widely used red light-emitting diode (LED) sources] and this is reflected in patient preference for PDT over alternative treatments. Nevertheless, the potential for this degree of pain is not ideal for patient care; thus, information on predictive factors and suitable methods of pain relief are required.
Predictive factors of photodynamic therapy-induced pain
Patient, lesion and treatment site characteristics 32, 33 indicate that higher PDT-induced pain scores may be observed when treating these conditions. Thus, it is important to have an awareness of this to minimize any potential impact on treatment delivery and to ensure that patients are appropriately advised and managed. One study also indicated that there was an association between more severe pain and the degree of erythema in the pretreated lesion.
14 However, this association has not been found by other investigators. 21 Likewise, while Lindeburg et al.
reported that the second treatment was more painful than the first in 38 patients treated with PDT, 34 it has, again, not been confirmed by other investigators. 16, 21, 35 The study of Sandberg et al. also showed that lesions that responded best to PDT were associated with more pain, 14 and it may be intuitive to consider that the more photosensitizer uptake and the greater lesional fluorescence and subsequent phototoxic insult might well lead to the best therapeutic outcome. However, this is not the case when treating AK on the dorsal hands with PDT, as increasing protoporphyrin IX (PpIX) accumulation does not improve efficacy of treatment but increases adverse effects. 36 Subgroup analysis of the larger, multicentre, randomized controlled trials (RCTs) of efficacy of PDT, particularly in dysplasia and superficial nonmelanoma skin cancer, have not been undertaken to investigate whether there is an association between fluorescence, phototoxic inflammation and subsequent therapeutic outcome. Certainly, there is some evidence in smaller studies of a correlation between the degree of fluorescence intensity and pain experienced during PDT, 37 and this has been shown in acne vulgaris and in AK. 28, 38 In the latter study, the association with pain was shown between both the degree of PpIX fluorescence and the fluence rate of light delivery, and this is supported by other investigators. 16 Furthermore, pain is not required for PDT efficacy, as exemplified by dPDT, which is considered to be owing to the lower irradiance of daylight and of low level of continuous photoactivation of PpIX.
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The influence of prodrug on photodynamic therapyinduced pain
In a double-blind, RCT investigating forearm sites that had been tape-stripped in healthy volunteers, pain was higher on sites exposed to ALA than MAL. In addition, ALA induced higher levels of fluorescence, and there was a greater decrease in fluorescence with irradiation. 40 In a separate study, the same group compared the pain associated with MAL-PDT with ALA-PDT for acne and AK, and showed that the pain experienced was greater with more intense PpIX fluorescence and with a higher rate of light delivery. 38 This greater level of PpIX accumulation and fluorescence associated with ALA has consistently been reported, both in normal skin [40] [41] [42] [43] and diseased skin. 28 In addition to higher levels of phototoxicity occurring in normal skin following ALA-PDT compared with MAL-PDT, more prolonged hyperpigmentation may also occur with the former. 43 However, when analysing studies in which MAL-PDT and ALA-PDT have been compared directly, usually there have been other variables, in particular the duration of application of the prodrugs. 44, 45 Indeed, two small studies comparing ALA-PDT and MAL-PDT when used for nodular BCC and acne with application for 3 h in each, showed no differences in acute pain scores between the prodrugs, 28, 46 although there was greater pain associated with ALA-PDT at 24 h post-treatment in the acne study. 28 More recently, in a large, multicentre study comparing ALA in nanocolloid emulsion (BF-200 ALA) with MAL-PDT, there was no significant difference in adverse effects seen between the prodrug treatment arms. 47 Reduction of drug concentration and/or incubation time may also be considered for effective, less painful PDT, as may be employed for AK or acne. [48] [49] [50] With the development of newer formulations of topical prodrugs and lower drug dose regimens, vigilance is required to ascertain whether any change in depth of effect and efficacy may also be associated with changes in pain experienced and tolerance of treatment.
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The influence of light delivery on photodynamic therapyinduced pain
Most topical PDT is undertaken using LED light delivery. There are few studies in which laser light delivery has been compared with noncoherent broadband light sources, although the evidence from two studies, one of which was retrospective, indicated no significant difference in efficacy or adverse effects, which included pain. 11, 54 Certainly, in vitro and in vivo studies support the safety profile of LED light delivery.
55,56 Carija et al. undertook a within-patient, prospective, controlled study of LED PDT with pulse-dye laser PDT in 15 patients with 62 BCC lesions. 57 While there were similar pain scores between the treatment arms, lower clearance rates were seen at 12 months with pulse dye laser PDT.
In the large, multicentre study comparing BF-200 ALA-PDT and MAL-PDT for AK, 47 more adverse effects were observed in patients treated with a narrower spectrum LED source than in those treated with a broader spectrum, albeit without longer-term safety concerns. 58 Investigators have shown that variable pulsing of light delivery may reduce the pain associated with MAL-PDT for AK in a prospective, controlled study that also showed no loss of efficacy or change in patient satisfaction. 59 Other variables of light delivery have been studied, including the use of filtering of infrared in one study of 80 participants, which was associated with less pain than conventional LED PDT, without loss of efficacy.
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Most dermatological PDT uses red light for delivery of depth of effect, but the wavelengths included do impact on PDT-induced pain. In one AK study where green and red light PDT were compared, less pain was experienced using the former with no loss of efficacy in this superficial indication. 61 However, a similar study comparing green and red light for SCC in situ showed loss of efficacy with green light and no significant difference in pain. 62 Mikolajewska et al. undertook a study in 10 healthy volunteers exposed to topical ALA and MAL for 24 h and irradiation was undertaken using either violet laser light or red laser light. 63 In this study, greater pain was experienced in association with red light and a more persistent erythema seen for ALA-PDT, although these differences were not seen in the sites treated with MAL-PDT. However, the results have not been followed up with investigations in diseased tissue and the relevance of this in the clinical setting is unclear. There does not seem to be a strong association between pain experienced during PDT and total light dose used, and this likely reflects the fact that pain is maximally experienced in the first half of irradiation. [64] [65] [66] Thus, simply reducing the total dose used is unlikely to impact significantly on the tolerance of treatment. However, there is substantial evidence that lower irradiance light delivery during PDT, such as dPDT or reduced irradiance hospital or portable device light delivery, is at least as effective as conventional higher irradiance regimens. 38, 39, [67] [68] [69] [70] [71] [72] [73] It seems that at lower irradiances, particularly < 50 mW cm À2 , less pain is experienced during PDT. 16, 38, 39, [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] In particular, the use of dPDT has been compared with conventional PDT in large, within-patient, multicentre studies, most recently in Europe and Australia involving patients with mild-to-moderate field-change AK. 78, 79 An overall consensus indicates that dPDT to large areas of AK is extremely well tolerated, with much lower pain scores than for conventional PDT, and that efficacy rates are similar. 71 In addition, in support of the use of low irradiance PDT, preliminary data obtained from non-comparative, open studies of low irradiance portable ambulatory LED devices indicate that pain scores are also very low and efficacy at 1-year follow-up is high. 67, 72, 73, 80 These are important developments for the use of PDT in situations where pain previously could have been a treatmentlimiting factor. This now enables larger areas to be treated in a well-tolerated and an almost painless, effective regimen with dPDT. Another alternative means of varying irradiance using conventional hospital-based LED devices is with use of an initially reduced irradiance at < 50 mW cm À2 , and, thereafterfor the latter part of the regimen -to increase irradiance in order to deliver an overall effective light dose. This approach of increasing irradiance during PDT after an initial lower (< 50 mW cm À2 ) irradiance approach to light delivery may be associated with reduced pain scores and can be useful, for example, if treating genital or perineal sites. 81 This was investigated in a retrospective, single-arm study of 14 patients treated with this two-step irradiance regimen for BCC and SCC in situ, showing high clearance rates. 82, 83 Fractionation of light has also been investigated as a means of improving efficacy of PDT, 84 although this has been shown to be at the expense of increased adverse effects, notably pain.
Pain: how does photodynamic therapy compare with other treatments?
When looking at the outcome of severe pain which requires a break in treatment or use of local infiltration anaesthesia, PDT results in significantly higher pain scores compared with placebo. 29, 47, 85, 86 This is also the case for lower levels of more manageable pain. Furthermore, when comparing dPDT with conventional PDT, the former is significantly less painful, based on large, multicentre studies. 39, 71, 74, 78, 79 In the larger studies comparing the outcome of severe pain, which requires a break in treatment or use of local infiltration anaesthesia, no significant differences were seen between cryotherapy, 5-fluorouracil or imiquimod, 35, [87] [88] [89] whereas less pain was experienced with surgical excision than with PDT, although this would be expected as local anaesthesia is used for the surgical procedure. 90, 91 Of note, the pain and discomfort of other topical treatments, such as 5-fluorouracil or imiquimod, is not directly comparable with PDT; the former are associated with increasing discomfort and inflammation during the course of treatment, over several weeks, whereas the pain experienced by PDT is maximal in the first few minutes of treatment and then subsides rapidly. 35, 92 This is an acute, rather than a more chronic experience, probably indicating why patient satisfaction levels with PDT are high. 92 Thus, when MAL-PDT was compared with ingenol mebutate for treatment of multiple AKs on the face and scalp in withinpatient, split-face studies, pain scores and cosmetic outcome were higher with PDT, but local skin reactions were more severe and persistent with ingenol mebutate; overall, patients preferred PDT. 93, 94 When dPDT was compared with ingenol mebutate in 27 participants with AK in a within-patient study, pain scores were higher for ingenol mebutate. 95 Similar efficacy was reported between the two groups but increased tolerance for dPDT was documented in terms of reduced local skin reactions and pain, and preference for dPDT. 95 Furthermore, in a randomized, observer-blinded, withinpatient comparison of patients with multiple AKs treated with trichloroacetic acid compared with ALA-PDT, higher pain scores and efficacy rates were seen with PDT and scarring was present only in those treated with trichloroacetic acid. 96 Pain relief for photodynamic therapy-induced pain
Treating with methods of no significant benefit
Given the nature of PDT-induced pain and the probable neurogenic mechanisms involved, it may be anticipated that topical anaesthesia could be beneficial for pain relief during PDT. However, in a within-patient, double-blind RCT of ALA for extensive AK on the scalp, Langan and Collins failed to show a significant effect of eutectic mixture of local anaesthetics (EMLA) for PDT-induced pain. 97 This is supported by the observations of Grapengiesser et al. in 60 patients in whom EMLA was used during PDT. 13 A separate interindividual study by Holmes et al. found no significant effect of tetracaine gel (Ametop â ; Perstorp Speciality Chemicals AB, Perstorp, Sweden) used topically during ALA-PDT for superficial BCC, SCC in situ or AK. 98 Likewise, during large-area PDT for facial AK and field-change carcinogenesis, no benefit of topical lidocaine hydrochloride 3% cream was found. 99 In a randomized, double-blind, placebo-controlled study, morphine gel 0Á3% was shown not to be significantly beneficial for pain relief during topical MAL-PDT; 100 Sandberg et al. observed that capsaicin cream was also not significantly effective in reducing pain and there were side-effects of the topical capsaicin itself. 14 
Treating with methods of potential benefit
In contrast, a pilot, open, split-face study performed by Borelli et al. on the use of subcutaneous infiltration of ropivacaine 1% with prilocaine 1% for PDT pain relief showed benefit, although there were significant adverse effects of cheek swelling persisting for up to 3 days, which could limit its use. 101 This has been supported in a separate case report showing the benefit of subcutaneous anaesthesia for pain relief during PDT in a 7-year-old child. 102 In addition, peripheral nerve blockade can be significantly effective in reducing PDT-induced pain when used for extensive facial AK. In an initial study in 16 patients with symmetrical facial AK, nerve blockade using mepivacaine and adrenaline was used to block supraorbital, supratrochlear, infraorbital and mental nerves, and the nonanesthetized side served as control. Pain scores were significantly reduced on the anaesthetized side and 15 of the 16 patients expressed preference for nerve blockade in future if PDT was required. 103 This has also been supported by a separate study in 10 male patients with facial AK, using supraorbital, supratrochlear and occipital nerve blockade during MAL-PDT. 104 In an open clinical trial involving 34 patients with frontal facial AK where supraorbital and supratrochlear nerve blockade was used on one side and cold air analgesia on the other, nerve blockade was significantly superior with respect to pain relief, and preferred in 31 of the 34 patients. 105 However, nerve blockade is only possible at certain body sites, and, of course, requires an additional invasive procedure; as such, it may not be appropriate for many patients treated with PDT. In a prospective, controlled, observational study to address the potential effect of nitrous oxide (NO), involving 71 patients treated with MAL-PDT for multiple AKs on the cheeks, all patients received 800 mg ibuprofen 30 min before PDT irradiation. In addition, cooling was used with a cold-air fan and interruptions in treatment were allowed if required and, for patients who experienced severe pain (visual analogue scale score ≥ 6), despite ibuprofen and cooling air, additional NO and oxygen mixture (Livopan â ) was offered for PDT to the other cheek. Overall, a reduction in pain score of 55Á2% was seen between treatments to the first and second cheek following application of the NO and oxygen mixture. Treatment was generally well-tolerated, although six of 30 patients (20%) experienced mild side-effects during inhalation of the NO and oxygen mix, which included vertigo, fear of loss of control and amplification of noise. 106 Considering other options for pain relief during PDT, investigators have explored the potential use of transcutaneous electrical nerve stimulation (TENS). This was undertaken in a pilot study in 14 patients with facial and scalp AK who had experienced severe pain during earlier PDT treatments. When the TENS electrodes were placed on the shoulders, four patients found no benefit from the use of TENS and three patients (21%) who had had previous interrupted PDT sessions due to pain were able to complete treatment, although the reduction in pain scores was modest (from 8Á1 to 6Á2). Overall, all but one patient would have used TENS again during PDT. This pilot study requires further investigation, although TENS is only feasible at certain body sites and therefore may have limited application in routine clinical use. 107 In many PDT regimens, use of a cold-water spray is employed as a routine measure during PDT. In a double-blind, controlled study involving 85 patients treated with ALA-PDT for AK or acne vulgaris, two thermal spring waters were investigated and sprayed four times daily to the face for 1 week after PDT. A reduction in discomfort, pain and erythema was experienced between days 2 and 7, although no impact was shown on the period of maximal pain, which was on day 1. 108 In a separate study of 24 patients with AK treated with MAL-PDT on two symmetrical areas, cooling with either coldwater spray or a cold-water pack was employed in either the first or second period of illumination. The water spray and cool pack reduced mean pain scores modestly by 1Á2-1Á3 points; however, pausing irradiation was associated with a higher reduction in pain of 3-3Á7 points. Thus, while cooling resulted in minor reduction in pain intensity, a pause in illumination was more effective for pain relief, and these are relatively easy things that can be incorporated routinely into clinical PDT practice. 109 Pausing during illumination may also be useful when treating acne with PDT. 51 The relatively small impact of cooling air on reduced PDT-associated pain was also shown by Stangeland and Kroon, who undertook an open, within-patient, right-left comparison study in 43 patients treated with MAL-PDT for field change cancerization, showing a small but significant reduction in pain scores in those treated with cold air analgesia. 110 These observations of the utility of cooling are supported by a nonrandomized, retrospective, observational, controlled study in which cooling devices were seen to be associated with reduced PpIX photobleaching. However, a reduction in disease clearance rate was seen at 3 months of follow-up and thus cooling should be used with caution because of concerns about adverse impact on therapeutic effect.
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Other treatment methods
Less conventional approaches have included a plant-derived spray that contained camomile and menthol, which was used in addition to glycolic acid. A randomized, blinded study involving 56 patients with field-change cancerization of either arm (n = 25) or face (n = 31) showed reduced pain scores at all time points up to 30 min, during and after treatment. The sprays were applied to treatment areas 10 min before irradiation and at any time during irradiation, with the placebo being a coffee-scented saline spray. 112 While this may be a relatively simple method to reduce discomfort when large areas are treated with PDT, it needs further study. While PDT is generally well tolerated, exploring options for patients who have found PDT to be painful is worthwhile. A single session of hypnosis was explored in a pilot study of 12 patients treated with PDT for precancerous lesions (actinic keratosis, SCC in situ, Bowenoid papulosis and Paget disease), showing significantly reduced pain scores in eight patients, six of whom had previously experienced PDT without hypnosis. While it would not be required for most patients treated with PDT, hypnosis requires further investigation as it could be considered in exceptional circumstances if proven to be effective. A limitation would be the requirement for members of staff to be trained adequately in hypnosis. 113 Thus, while nerve block, subcutaneous infiltration with anaesthetic, TENS, cooling air and/or pausing irradiation may be of benefit, more typical forms of topical anaesthetics or oral analgesics have not been shown to be effective. 20, 114 Modifying PDT regimens to employ lower irradiance light delivery is usually most effective, enabling successful treatment.
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Phototoxicity of topical photodynamic therapy
The inflammatory reaction following PDT is expected as a consequence of the phototoxic effect. This usually manifests as erythema and oedema, and sometimes with associated wheal and flare, i.e. an urticarial reaction. 116, 117 Persistence of erythema may be seen for some months after treatment. 11 Crusting, infection, sterile pustules and erosions are also uncommon adverse effects. 118 In a study involving 10 healthy volunteers, erythema induced by ALA-PDT peaked at 1-2 h after stopping irradiation, 6 although laser Doppler studies have shown that the increase in blood flow that occurs immediately after topical PDT persists for a week. 119 Marked interindividual variability is seen in phototoxic reaction and there are also body sites effects, with reports of increased phototoxic reactions midface, 120 consistent with increased pain at this site. 22 Phototoxic inflammation seems to be greater following the application of ALA rather than MAL. In a randomized comparison of ALA-PDT and MAL-PDT involving 34 healthy volunteers, a composite score of erythema, oedema and pigmentation was significantly greater for ALA-PDT than for MAL-PDT, which likely reflected the increased pigmentation seen with ALA-PDT, persisting for 4 weeks. 43 Detailed investigation of ALA-PDT-induced phototoxicity in normal human skin indicated the release of histamine, accompanying an early urticarial phase, although cetirizine showed no effect on the erythemal response at 24 h. 4 Consistent with this is the occurrence of clinically reported urticaria seen immediately, during and after topical PDT in a small proportion of patients, and possibly being more likely in those with severe photodamage. The incidence of urticaria has been reported to be between 0Á9% and 3Á8%, and antihistamines may be of some benefit when used prophylactically for itch and wheal. 121, 122 Prominent phototoxic erythema, associated with malaise and flu-like symptoms, was recently reported in two organ transplant recipients treated with PDT for photodamage. 123 While there is significant evidence of an association between prodrug-induced fluorescence, phototoxicity and pain, 21, 38, 124, 125 an association between phototoxicity and therapeutic outcome is less clear cut. An association between PpIX photobleaching and clinical outcome at the 3-month follow-up after PDT treatment was observed in a pilot study in diseased skin. 126 In a separate study involving 24 healthy volunteers, forearm skin was tape-stripped and during different times of incubation of MAL, fluorescence photobleaching was assessed during red light irradiation. A significant correlation was seen between the incubation time of the prodrug and time to illumination and photobleaching; there was also a significant correlation between photobleaching and erythema, and between photobleaching and pain. These imply that shorter incubation periods of the prodrug may result in reduced pain, although impact on efficacy in diseased skin is unclear. 127 In addition, reduced MAL concentration may also reduce any potential for increased pigmentation. 128 In a study of 22 patients with field change mild AK on the face and scalp, the application of MAL for 30 min vs MAL for 3 h, with both sites then irradiated at 3 h, was investigated. The application of a super-potent corticosteroid before and after PDT to the short application, pulsed PDT site was also investigated. The reduction of MAL application time and the use of topical corticosteroid reduced PDTinduced erythema at 24 h but did not impact on efficacy at 3 months. 129 The same group studied 22 patients with facial and scalp AK separately and also showed that application of a super-potent corticosteroid reduced the inflammation and erythema of PDT but did not impair efficacy. 130 Furthermore, during dPDT, using light protection of the skin following PDT appears to reduce inflammation, although its impact on efficacy is unclear. 131 It is also of interest to note that brimonidine tartrate gel may also have the potential to reduce erythema after dPDT, although its impact on efficacy, again, is unknown.
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Patient satisfaction, tolerance and cosmetic outcome
High levels of patient satisfaction are reported for PDT, although pain may impact on patients' perception of the treatment. 78, 79, 88, 92, [133] [134] [135] [136] [137] [138] [139] Improved tolerance and satisfaction with PDT was reported in one randomized study comparing PDT with imiquimod for AK. [140] [141] [142] Improved preference for PDT compared with cryotherapy was reported in a RCT, with a 5-year follow-up, comparing MAL-PDT with cryotherapy for superficial BCC. 88 MAL-PDT compares favourably with ingenol mebutate when used for AKs on the face and scalp, with superior cosmetic outcomes and an overall patient preference for PDT, owing to higher pain scores and local skin reactions being more severe and persistent with ingenol mebutate. 93, 94 Similarly, when dPDT was compared with ingenol mebutate in 27 participants with AK in a within-patient study, the former was better tolerated and preferred, and was associated with fewer adverse effects; efficacy was similar between the two modalities. 95 When comparing trichloroacetic acid with ALA-PDT for scalp AK, higher efficacy rates and pain scores were seen with PDT and scarring was present only in those treated with trichloroacetic acid. 96 
Allergic contact dermatitis to prodrugs
Topical PDT induces an inflammatory reaction consisting of erythema, often with some oedema and subsequent crusting; these are expected effects of topical PDT. The degree and severity often reflect the severity of photodamage and the area that is treated. While it could be the development of an irritant dermatitis, the possibility of the patient becoming sensitized and having developed allergic contact dermatitis to the prodrug should be considered, especially with a prolonged and persistent inflammation following PDT. There are independent reports of allergic contact dermatitis arising to MAL. [143] [144] [145] [146] [147] [148] [149] In one study, positive patch testing to MAL cream (but not to placebo) was seen, indicating that this is likely to be due to the prodrug itself and not the excipient. 147 The risk of sensitization is predicted to be of the order of 1-2%. 146, 147 However, it is important to be aware of this possible adverse effect as a more generalized dermatitis can occur if this is not recognized and PDT is continued. 145, 150 Contact dermatitis to MAL has been reported and, more recently, to BF-200 ALA. 149 Reviewing the separate studies, the risk of sensitization is increased in those patients who have had multiple treatments with PDT and large areas treated. 147, 149 It is important to be aware of and have a low threshold for considering patch testing in patients who develop a more severe or atypical reaction to PDT. With increasing use of dPDT for large-area treatment it would be wise to be vigilant in this patient group.
Medium-term adverse effects
The relative selectivity of PDT and the observation from large, multicentre studies that healing and cosmetic outcome are good mean that PDT is often selected as the treatment of choice to use for large areas and at difficult sites, such as lower legs, where healing may be problematic. 78, 79, 88, 92, [133] [134] [135] [136] [137] [138] [139] While changes of fibrosis can be seen histologically following PDT, 151 scarring is rarely reported; 88, [137] [138] [139] 152 indeed, PDT has been explored for its use in scar remodelling and potential to treat keloid scar, 153, 154 although this requires further investigation.
Rarely, milia cysts may occur following PDT if the basal membrane is disrupted; this may be difficult to distinguish from recurrent BCC, 155 but, in practice, this is an occasional adverse effect.
In early studies of the use of high-intensity PDT regimens for acne vulgaris, biopsy evidence of destruction of sebaceous glands was observed, 156 although current acne regimens are of lower intensity with regard to irradiation. As such, it is anticipated that the risk of permanent damage to sebaceous glands will be lowered, although further studies with histological evidence of this have not been undertaken. Sterile pustules are often reported following PDT for acne vulgaris, although true infection is rarely seen, 28, 29 probably because of the antiinfective effects of PDT. Photo-onycholysis is well recognized with drug phototoxicity such as with psoralens, 157 and there are isolated reports of photo-onycholysis occurring following PDT when this has been undertaken at periungual sites, such as for viral warts and AK, 158, 159 and even one case arising following blue-light ALA-PDT to AK on the face. 160 
Pigmentary problems
Dyspigmentation may occur following PDT. In trials involving AK, extramammary Paget's disease, warts and acne, pigmentary changes have been observed, although are not usually prominent. 51, [161] [162] [163] Hyperpigmentation may occur, 43 which seems particularly likely with darker skin phototypes, and has been seen in the context of using PDT for acne vulgaris. 156, 164 However, in light-skinned populations, hyperpigmentation is rarely seen. 152 It is also not clear whether combining PDT with any pretreatment steps may increase the risk of pigmentation. In one study, while there was a trend to increased pigmentation with carbon dioxide laser-assisted PDT, this was not significantly different from PDT alone. 161 If hyperpigmentation occurs, it is usually reversible over some weeks. In one study, biopsy of PDT-induced pigmentation showed histologically increased numbers of activated melanocytes. 165 Hypopigmentation may also occur, presumably as a postinflammatory insult, although this is rarely a problem clinically.
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Hair problems
If PDT is undertaken at hair-bearing sites such as the scalp or beard area, there is potential for hair loss, and this has been observed following PDT treatment of large areas of SCC in situ and BCC. 166 However, this is not well reported in the literature but may be worth keeping in mind with regard to warning patients of this potential side-effect at the relevant treatment sites. Paradoxically, topical PDT may also increase hair growth, and one of the early studies of topical PDT was using haematoporphyrin derivative and ultraviolet A irradiation as an attempt to treat areas of alopecia areata. 167 Although that initial study was encouraging, subsequent studies have been disappointing, showing no convincing efficacy. 168, 169 However, one report of a study in mice indicated that the presence of iron was required with ALA to stimulate hair growth, although this has not been investigated in humans. 170 
Miscellaneous
Thus, while the main adverse effects of PDT are pain, which can usually be minimized through modification of treatment approaches, and the expected inflammatory phototoxic reaction, there have been rare reports of other miscellaneous adverse effects. PDT has been used to treat erosive pustular dermatosis, but there are also reports of the development of erosive pustular dermatosis of the scalp occurring within 1-3 months of PDT treatment of AK of the scalp. 171, 172 The possibility that this may be triggered by the insult of PDT thus exists. Possibly via similar mechanisms, localized bullous pemphigoid developing 3-4 months following PDT has also been observed. 173, 174 In the more recent study, the patient additionally developed blistering lesions at nontreatment sites, 174 and in both cases, while it is possible to speculate that the trigger may have been PDT, it is not clear cut and may have been coincidental. Likewise, a case of pemphigus vulgaris developing 1 week after a third PDT session at an adjacent site raises the possibility of an association, although, again, it may have been coincidental as the condition generalized. 175 The antimicrobial effects of PDT are increasingly being explored, and infection following PDT is unusual and less likely than with other topical therapies. 89 Interestingly, despite a report of reactivation of herpes simplex virus (HSV) at the treatment site, 24-48 h after PDT for AK on the forehead, 176 topical ALA-PDT has also been investigated in eight patients with recurrent HSV infection (oral and genital), with encouraging preliminary data suggesting that PDT may have therapeutic and preventative effects in reduction of HSV recurrence; this warrants further study. 177 There was one report of a peripheral nerve palsy developing 1 week after a second treatment session with MAL-PDT for facial AK (forehead, cheek and jaw). 178 Other causes of facial palsy were excluded and, despite systemic corticosteroids, the patient had no clinical improvement in the facial palsy at the 16-month follow-up. While this may have been coincidental, the occurrence on the same side of treatment, just 1 week post-treatment, raises the possibility of causal association; this could be either due to a direct traumatic effect of PDT on the superficial facial nerve branches or through viral reactivation, although there was no evidence of this in this case. There were also four cases reported of cellulitis developing after treatment of AK with PDT. 179 There was a report of five patients who developed transient memory impairment and global amnesia immediately after PDT for AK. 180 This did not appear to be associated with pain, and the neurological symptoms all resolved without sequelae within 24 h; the patients were investigated and no significant neurological or vascular disease was found. Three of the five patients had elevated blood pressure immediately post-treatment, 180 which has been documented in a separate report, including what was documented as hypertensive crisis in four patients after MAL-PDT. All had known hypertension and were on medication for this. 181 This latter observation is of interest in that blood pressure measurements are not undertaken routinely before, during or after MAL-PDT, but perhaps monitoring of hypertensive patients should be considered. Rarely, systemic flu-like symptoms may occur, with a report of intense phototoxic reactions and systemic malaise in two immunosuppressed patients following PDT and this has not previously been reported, so potentially there is a need to more actively enquire about this in patients who are severely photodamaged, possibly immunocompromised and receiving PDT to large areas. 123 
Carcinogenesis
While in vitro PDT may have cytotoxic and genotoxic effects, 182,183 the porphyrin-derived molecules used in topical PDT can also have both antioxidant and antimutagenic actions. 184 In hairless mouse models, both MAL-PDT and hexylaminolaevulinate (HAL)-PDT have separately been shown to delay the time to development of SCC, using repeated treatment regimens, [185] [186] [187] although caution is required in extrapolating these data to the human setting; indeed, only marginal effects on delayed tumour development were seen with daylight PDT when using HAL. 188 However, in a split-face study involving 25 renal transplant recipients, repeated topical PDT at 6-monthly intervals for 5 years delayed the development of AK when used as primary prevention, supporting an earlier randomized, within-patient study. 189 In this earlier study involving 81 patients with AK treated with either MAL-PDT or lesion-specific therapy such as cryotherapy, the former significantly reduced the development of new AK, although the effect was not maintained at longer-term follow-up over 2 years. 190 While PDT does not have the same mechanisms of action as ultraviolet radiation (e.g. it does not activate p53 but upregulates p21), 191 it is immunosuppressive. 192, 193 The immunosuppressive effects of PDT appear to be reduced by lowering the irradiance of light delivery, and by nicotinamide. 194, 195 Unlike many cancer therapies, topical PDT is often repeated and there is no clear evidence of a cumulative toxic effect. However, there are observations of the development of eruptive keratoacanthomas after PDT, [196] [197] [198] which may be in association with the trauma inflicted on the skin by PDT aggravating or provoking the development of keratoacanthoma. 199 There are reports of the development of invasive and sometimes poorly differentiated SCC arising within a few months of PDT treatment. [200] [201] [202] There are also isolated reports of melanoma developing at the site of PDT, 203, 204 and of a microcystic adnexal carcinoma developing at a site of SCC in situ treated by PDT several years earlier. 205 However, given that the majority of these patients had pre-existing, extensive field change, with precancerous and cancerous change, as well as a history of skin malignancies, association with PDT itself is very difficult to prove and these may well be coincidental cases. Likewise, the development of SCC arising after PDT for erythroplasia of Queyrat of the penis, as an isolated report, 206 may also have been coincidental. A recent retrospective study assessing cases of invasive SCC arising in areas previously treated by topical MAL-PDT identified 10 SCCs in 699 treated patients with no significant histological or immunohistochemical differences vs SCC lesions developing in non-PDT-treated areas. The patients who developed SCC all had multiple AK or SCC in situ and hence were predisposed to invasive SCC development, although an association with multiple (median of five treatments over 1 year) PDT sessions is highlighted. 207 However, vigilance is required, and reporting is to be encouraged. While longer-term follow-up of patients receiving PDT is ideal, it is often not practical as patients are often elderly and frail, and there are pressures on outpatient services.
Safety aspects of topical photodynamic therapy
Contraindications to PDT include a history of porphyria and allergy/photoallergy to the photosensitizer prodrug preparations or the active ingredients. 144, 146, 149 Most PDT is carried out using red light, which is not phototoxic to the retina. However, blue light can pose a hazard to the retina, potentially causing irreversible damage to the photosensitive neurotransmitters in the macula. 208 Wearing goggles, for both patient and staff, is recommended to limit the transmission of high-intensity light and to avoid discomfort and disturbance of colour perception. Following topical PDT, localized photosensitivity can remain for up to 48 h.
125,209
Conclusions
In summary, topical PDT is a widely used and evaluated therapy, which is generally very well tolerated by most patients. While pain and discomfort during irradiation are the main adverse effects during conventional PDT, adjustment of irradiation regimens, including the use of low-irradiance options such as dPDT, generally ensures that PDT can be administered effectively and safely. Other expected skin phototoxicity effects, notably erythema and oedema, resolve rapidly over a few days and longer-term adverse effects, such as pigmentary change, scarring or contact allergy, are uncommon. Thus, PDT has an important place in the management options of patients with superficial nonmelanoma skin cancer and dysplasia as highlighted in current guidelines. 
